Expression of 74-kDa histidine decarboxylase protein in a macrophage-like cell line RAW 264.7 and inhibition by dexamethasone

被引:21
作者
Hirasawa, N [1 ]
Murakami, A [1 ]
Ohucli, K [1 ]
机构
[1] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pathophysiol Biochem, Aoba Ku, Sendai, Miyagi 9808578, Japan
关键词
histidine decarboxylase; dexamethasone; MAP (mitogen-activated protein) kinase; RAW; 264.7; cell;
D O I
10.1016/S0014-2999(01)00931-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Stimulation of RAW 264.7 cells with the Ca2+-ATPase inhibitor thapsigargin increased histamine production. Immunoblot analyses revealed that thapsigargin increased the expression of 74-kDa histidine decarboxylase protein although rat mast cell line RBL-2H3 cells express both 74- and 53-kDa histidine decarboxylase proteins. The inhibition of histamine production by the mitogen-activated protein kinase-extracellular signal-regulated kinase kinase (MEK) inhibitors PD98059 (2 ' -amino-3 ' -methoxyflavone) and U0126 (1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene) and by the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1 H-imidazole) was correlated with the inhibition of the expression of thapsigargin-induced 74-kDa histidine decarboxylase protein. The synthetic glucocorticoid dexamethasone inhibited thapsigargin-induced histamine production and 74-kDa histidine decarboxylase protein expression. The thapsigargin-induced activation of p42/p44 MAP kinase and p38 MAP kinase was also inhibited by dexamethasone. These findings indicate that the induction of histamine production by thapsigargin in RAW 264.7 cells is due to the increased expression of 74-kDa histidine decarboxylase protein and that dexamethasone inhibits thapsigargin-induced histidine decarboxylase protein expression and histamine production via inhibition of MAP kinase activation. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 16 条
[1]  
AOI R, 1989, IMMUNOLOGY, V66, P219
[2]   THE INFLUENCE OF HISTAMINE ON IMMUNE AND INFLAMMATORY RESPONSES [J].
BEER, DJ ;
MATLOFF, SM ;
ROCKLIN, RE .
ADVANCES IN IMMUNOLOGY, 1984, 35 :209-268
[3]  
Hirasawa N, 1998, J IMMUNOL, V161, P4939
[4]  
HIRASAWA N, 1990, J IMMUNOL, V145, P3041
[5]   ANTITUMOR PROMOTION AND ANTIINFLAMMATION - DOWN-MODULATION OF AP-1 (FOS JUN) ACTIVITY BY GLUCOCORTICOID HORMONE [J].
JONAT, C ;
RAHMSDORF, HJ ;
PARK, KK ;
CATO, ACB ;
GEBEL, S ;
PONTA, H ;
HERRLICH, P .
CELL, 1990, 62 (06) :1189-1204
[6]   NEW APPROACHES TO PHYSIOLOGY OF HISTAMINE [J].
KAHLSON, G ;
ROSENGREN, E .
PHYSIOLOGICAL REVIEWS, 1968, 48 (01) :155-+
[7]   PHARMACOLOGICAL ANALYSIS OF THE VASCULAR-PERMEABILITY RESPONSE IN THE ANAPHYLACTIC PHASE OF ALLERGIC INFLAMMATION IN RATS [J].
OHUCHI, K ;
HIRASAWA, N ;
WATANABE, M ;
TSURUFUJI, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 117 (03) :337-345
[8]  
Rider LG, 1996, J IMMUNOL, V157, P2374
[9]   NEW ROLE FOR HISTAMINE IN INTERLEUKIN-3-INDUCED PROLIFERATION OF HEMATOPOIETIC STEM-CELLS [J].
SCHNEIDER, E ;
PIQUETPELLORCE, C ;
DY, M .
JOURNAL OF CELLULAR PHYSIOLOGY, 1990, 143 (02) :337-343
[10]   FUNCTIONAL ANTAGONISM BETWEEN ONCOPROTEIN C-JUN AND THE GLUCOCORTICOID RECEPTOR [J].
SCHULE, R ;
RANGARAJAN, P ;
KLIEWER, S ;
RANSONE, LJ ;
BOLADO, J ;
YANG, N ;
VERMA, IM ;
EVANS, RM .
CELL, 1990, 62 (06) :1217-1226